This report delivers the latest trends in the domestic and international medical device industry as of May 1, 2026. We will highlight carefully selected topics, from the approval of groundbreaking new products and industry-leading M&A activities to regulatory trends shaping the future of medicine.
1. BioticsAI Receives FDA Approval for AI Ultrasound System for Fetal Anomaly Detection
News Highlights Medical AI startup BioticsAI has received U.S. Food and Drug Administration (FDA) approval for its AI copilot (diagnostic support system) that detects fetal developmental abnormalities during ultrasound examinations, and has begun full-scale implementation in hospitals [1] [2].
Industry Impact Obstetric ultrasound examination is a highly skilled field where even specialists face the risk of missing fetal abnormalities. BioticsAI's system detects and quantitatively analyzes abnormalities in real-time, reducing diagnostic errors and powerfully supporting physicians' decision-making. The company developed its initial prototype with less than $100,000 in funding and achieved FDA approval at an exceptional speed by integrating clinical validation and regulatory strategy from the early stages of product development [1]. This success story could serve as a new model case for the regulatory approval process for other startups developing Software as a Medical Device (SaMD).
2. Novocure's "Optune Pax" for Pancreatic Cancer Receives FDA Approval and U.S. Launch
News Highlights Novocure, a company developing Tumor Treating Fields (TTFields) therapy, announced that it has received FDA approval for its wearable therapeutic device "Optune Pax" for adult patients with locally advanced pancreatic cancer and has begun commercial rollout in the U.S. It is indicated for use in combination with chemotherapy (gemcitabine and nab-paclitaxel) [3] [4].
Industry Impact Pancreatic cancer is known for its extremely rapid progression and poor prognosis. The approval of Optune Pax provides a new non-invasive treatment option for this intractable cancer, and is expected to contribute to extending patient survival. The company's Q1 2026 financial results were positively impacted by the launch of this new product, and its full-year revenue guidance was also revised upward [4]. The company's unique position of "physical approach with medical devices" in cancer treatment is further strengthened.
3. Rohto Pharmaceutical Submits Application for Cytomegalovirus Keratoendotheliitis Treatment in Japan
News Highlights On April 30, 2026, Rohto Pharmaceutical Co., Ltd. submitted an application to the Ministry of Health, Labour and Welfare for manufacturing and marketing approval of "ROH-101 (generic name: ganciclovir)," an ophthalmic antiviral gel eye drop for cytomegalovirus (CMV) keratoendotheliitis [5] [6].
Industry Impact Cytomegalovirus keratoendotheliitis is a serious disease that can lead to irreversible corneal endothelial dysfunction and, in the worst cases, blindness if it progresses. Currently, there are no officially approved treatments for this condition, either domestically or internationally [6]. This drug has been designated as an orphan drug by the Ministry of Health, Labour and Welfare, and if approved, it will be the world's first dedicated treatment. This marks an important milestone in addressing the unmet medical needs in the domestic ophthalmic medical field.
4. Domestic Regulatory Trends: Enforcement of 2025 PMD Act Amendment and Strengthening of PMDA Review System
News Highlights As of May 1, 2026, parts of the amended Pharmaceuticals and Medical Devices Act (PMD Act) and other related laws, which were enacted in 2025, have come into force. This amendment includes provisions for strengthening governance for manufacturers and distributors of medical devices and pharmaceuticals (such as the establishment of an order to change responsible officers and the legalization of quality assurance managers) [7]. In addition, the Pharmaceuticals and Medical Devices Agency (PMDA) is continuously strengthening its review system for program medical devices and AI diagnostic support systems (such as AI for gastrointestinal endoscopy).
Industry Impact With the enforcement of the amended PMD Act, corporate management will be required to establish substantial and strict quality and safety management systems. Formal compliance will not be sufficient; management-led governance will be essential. On the other hand, the modernization of the PMDA's review system for AI and digital fields will promote the rapid practical application of innovative medical devices. Product development that adds the value of new software, such as AI, to existing hardware like gastrointestinal endoscopes, is expected to accelerate further.
References
[1] FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder | TechCrunch [2] BioticsAI won FDA approval and begins hospital rollout | Mezha.net [3] Novocure Reports First Quarter 2026 Financial Results | Novocure Investor Relations [4] Novocure outlines $690M-$710M 2026 revenue guidance as Optune Pax launch reaches 169 | Seeking Alpha [5] CMV角膜内皮炎治療薬を国内申請 ロート製薬 | 日刊薬業 [6] サイトメガロウイルス角膜内皮炎に対する治療薬「ROH-101（ガンシクロビル点眼ゲル剤）」に関する製造販売承認申請のお知らせ | ロート製薬株式会社 [7] 第16号 【2026年5月1日等施行】2025年薬機法等改正の全容（概要） | トムソン・ロイター
Need help with Japan's medical device approval?
Our regulatory affairs consultants specializing in digestive endoscopy devices provide end-to-end support from strategy to document preparation. Contact us for a free initial consultation.
Free Consultation